Drug Pricing Investigation
More on Drug Pricing Investigation
Washington, D.C. (May 24, 2023)—Rep. Jamie Raskin, Ranking Member of the Committee on Oversight and Accountability, led Democrats in addressing the role of Pharmacy Benefit Mangers (PBMs) in high drug prices and calling for action to build on Democrats' work to lower prescription drug prices and expand access to affordable health care.
Washington, D.C. (April 7, 2022)—Today, Rep. Carolyn B. Maloney, Chairwoman of the House Committee on Oversight and Reform, Sen. Debbie Stabenow, Chairwoman of Senate Finance Subcommittee on Health Care, and Sen. Tina Smith led colleagues—including Rep. Peter Welch and Rep. Jan Schakowsky—in introducing a package of legislation targeting business practices pharmaceutical companies use to suppress competition, maintain market monopolies, and keep drug prices high.
Washington, D.C. (Dec. 10, 2021)—Today, Rep. Carolyn B. Maloney, the Chairwoman of the Committee on Oversight and Reform, released the final staff report culminating the Committee's nearly three-year investigation into pharmaceutical pricing and business practices, which was launched by the late Chairman Elijah E. Cummings.
Washington, D.C. (December 3, 2021)— On Thursday, December 9, 2021, at 10:30 a.m., Rep. Carolyn B.